^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BMS-986253

    i
    Other names: BMS-986253, HuMax-IL8, HuMax IL8, HuMax-Inflam, MDX 018, MDX-018, HuMax-IL-8, BMS986253, BMS 986253, MDX018
    Associations

    News

    Trials
    Company:
    BMS
    Drug class:
    IL-8 inhibitor
    Related drugs:
    Associations

    News

    Trials
    11d
    CA027-002: A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers (clinicaltrials.gov)
    P1/2, N=281, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed
    Trial completion
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • BMS-986253
    3ms
    Spark2: Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Opdivo (nivolumab) • BMS-986253
    4ms
    Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov)
    P2, N=76, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Oct 2025 --> May 2026
    Trial primary completion date • IO biomarker
    |
    Opdivo (nivolumab) • cyclophosphamide • BMS-986253 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • urelumab (BMS-663513)
    5ms
    Nivolumab Combined With BMS-986253 in HCC Patients (clinicaltrials.gov)
    P2, N=13, Terminated, NYU Langone Health | N=23 --> 13 | Completed --> Terminated; Study was terminated early by the drug sponsor due to slow accrual and a change in the company's drug development priorities
    Enrollment change • Trial termination
    |
    Opdivo (nivolumab) • cabiralizumab (BMS-986227) • BMS-986253
    5ms
    A novel anti-PD-L1/IL-8 bispecific antibody BP2402 enhances antitumor immunity and modulates inflammatory signaling in triple-negative breast cancer mice model. (PubMed, J Transl Med)
    These results indicate that dual targeting of PD-L1 and IL-8 pathways represents a promising therapeutic strategy for TNBC. The bispecific antibody approach offers superior therapeutic potential by simultaneously modulating immune checkpoints, inflammatory signaling, and angiogenesis, effectively addressing resistance mechanisms. Additional preclinical optimization and clinical studies are required to fully assess the therapeutic potential of this novel immunotherapeutic approach.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • JAK1 (Janus Kinase 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    Tecentriq (atezolizumab) • BMS-986253
    5ms
    The Interleukin-8-CXCR1/2 Axis as a Therapeutic Target in Peritoneal Carcinomatosis. (PubMed, Curr Oncol)
    IL-8 targeting agents such as monoclonal antibodies (BMS-986253) and small-molecule inhibitors (SX-682, AZD5069, navarixin) have shown efficacy in mitigating tumor growth and improving the efficacy of immune checkpoint inhibitors. In this review, we discuss the influence of the IL-8/CXCR1/CXCR2 axis within the peritoneal immune environment in PC and highlight recent work using IL-8 or CXCR1/CXCR2 blockade as a therapeutic strategy for PC. Continued research into the peritoneal immune microenvironment and the development of targeted therapies are essential for improving the management and prognosis of PC, potentially enhancing antitumor immunity and patient outcomes.
    Review • Journal
    |
    IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
    |
    SX-682 • AZD5069 • BMS-986253 • navarixin (MK-7123)
    6ms
    NICHE: Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (clinicaltrials.gov)
    P2, N=353, Recruiting, The Netherlands Cancer Institute | N=268 --> 353 | Trial completion date: Dec 2024 --> Mar 2032 | Trial primary completion date: Dec 2024 --> Mar 2032
    Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016) • BMS-986253 • celecoxib oral
    8ms
    Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov)
    P2, N=76, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    Opdivo (nivolumab) • cyclophosphamide • BMS-986253 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • urelumab (BMS-663513)
    10ms
    Nivolumab Combined With BMS-986253 in HCC Patients (clinicaltrials.gov)
    P2, N=23, Completed, NYU Langone Health | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Jan 2025
    Trial completion • Trial completion date
    |
    Opdivo (nivolumab) • cabiralizumab (BMS-986227) • BMS-986253
    11ms
    Spark2: Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca (clinicaltrials.gov)
    P2, N=24, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Apr 2026 --> Sep 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • BMS-986253
    11ms
    Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas (clinicaltrials.gov)
    P2, N=76, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Aug 2026 --> May 2026
    Trial completion date • IO biomarker
    |
    Opdivo (nivolumab) • cyclophosphamide • BMS-986253 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • urelumab (BMS-663513)
    1year
    GCO 19-1754: Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, Icahn School of Medicine at Mount Sinai | Completed --> Active, not recruiting | Trial completion date: Nov 2023 --> Dec 2025 | Trial primary completion date: Nov 2023 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • BMS-813160 • BMS-986253